Jane Street’s Edgewise Therapeutics EWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-198,000
Closed -$6.24M 11974
2026
Q1
$6.24M Buy
198,000
+168,100
+562% +$4.85M ﹤0.01% 3182
2025
Q4
$742K Buy
+29,900
New +$600K ﹤0.01% 6814
2025
Q2
Sell
-19,000
Closed -$418K 9963
2025
Q1
$418K Sell
19,000
-9,400
-33% -$247K ﹤0.01% 7195
2024
Q4
$758K Sell
28,400
-132,500
-82% -$4.22M ﹤0.01% 5923
2024
Q3
$4.29M Buy
+160,900
New +$3.2M ﹤0.01% 3103

Other funds holding EWTX

Jane Street's EWTX Position: Q2 2026 in Review

Jane Street reduced its Edgewise Therapeutics (EWTX) stake by 16% in Q2 2026, selling an estimated $195K and leaving 29,934 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #6126.

Jane Street first reported a position in EWTX in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.34M in Q3 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Jane Street held 29,934 shares of Edgewise Therapeutics worth $1.22M as of Q2 2026.
  • Jane Street sold 5,644 Edgewise Therapeutics shares in Q2 2026, an estimated $195K.
  • Edgewise Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #6126 holding.
  • Jane Street first reported a position in Edgewise Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Jane Street's Edgewise Therapeutics position peaked at $1.34M in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.